Alopecia Clinical Trial 20223017

[LCID Study Number: 20223017]

A Phase 2a, Randomized, Double-Blind, Vehicle-Controlled, Single Site, Exploratory Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults with Frontal Fibrosing Alopecia

The purpose of this study is to evaluate the molecular signature changes following topical application of Delgocitinib in subjects with frontal fibrosing alopecia (FFA), as well as safety and preliminary efficacy.

Disease/Condition: Alopecia

Department: Dermatology

Location(s): Lahey Hospital & Medical Center (Burlington)

Primary Contact Email: sanjna.das@lahey.org